Prevalence of hepatic steatosis in women with polycystic ovary syndrome

Journal of Human Reproductive Sciences

Volumn 6, Issue 1, 2013, Pages 9-14

  Karoli, Ritu ^a   Fatima, Jalees ^a   Chandra, Ashok ^a   Gupta, Uma ^a   Islam, Faraz Ul ^a   Singh, Gagandeep ^a  

^a Era's Lucknow Medical College   (India)

Author keywords

Insulin resistance; metabolic syndrome; non alcoholic fatty liver disease; polycystic ovary syndrome

Indexed keywords

INSULIN;

ABDOMINAL RADIOGRAPHY; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY WEIGHT; CLINICAL EVALUATION; CONTROLLED STUDY; ECHOGRAPHY; FATTY LIVER; FEMALE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; LIVER DISEASE; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OVARY POLYCYSTIC DISEASE; PREVALENCE; WAIST HIP RATIO;

EID: 84878923671     PISSN: 09741208     EISSN: 19984766     Source Type: Journal    
DOI: 10.4103/0974-1208.112370     Document Type: Article

References (44)

1. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352: 1223-36.
2. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89: 2745-9.
3. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound Peripheral insulin resistance, Independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38: 1165-74.
4. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology 2006;43: S99-112.
5. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: An underrecognized cause of cryptogenic cirrhosis. JAMA 2003;289: 3000-4.
6. Targher G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: The plot thickens. Diabet Med 2007;24: 1-6.
7. Bellentani S, Bedogni G, Tiribelli C. Liver and heart: A new link? J Hepatol 2008;49: 300-2.
8. Agarwal N, Sharma BC. Insulin resistance and clinical aspects of non-alcoholic steatohepatitis (NASH). Hepatol Res 2005;33: 92-6.
9. Ahima RS. Insulin resistance: Cause or consequence of nonalcoholic steatohepatitis? Gastroenterology 2007;132: 444-6.
10. Bloomgarden ZT. Nonalcoholic fatty liver disease and insulin resistance in youth. Diabetes Care 2007;30: 1663-9.
11. Angelico F, Del BM, Conti R, Francioso S, Feole K, Fiorello S, et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2005;90: 1578-82.
12. Brown AJ, Tendler DA, McMurray RG, Setji TL. Polycystic ovary syndrome and severe nonalcoholic steatohepatitis: Beneficial effect of modest weight loss and exercise on liver biopsy findings. Endocr Pract 2005;11: 319-24.
13. Setji TL, Holland ND, Sanders LL, Pereira KC, Diehl AM, Brown AJ. Nonalcoholic steatohepatitis and nonalcoholic fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91: 1741-7.
14. Cerda C, Perez-Ayuso RM, Riquelme A, Soza A, Villaseca P, Sir-Petermann T, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol 2007;47: 412-7.
15. Gambarin-Gelwan M, Kinkhabwala SV, Schiano TD, Bodian C, Yeh HC, Futterweit W. Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol 2007;5: 496-501.
16. Preiss D, Sattar N, Harborne L, Norman J, Fleming R. The effects of 8 months of metformin on circulating GGT and ALT levels in obese women with polycystic ovarian syndrome. Int J Clin Pract 2008;62: 1337-43.
17. Brzozowska MM, Ostapowicz G, Weltman MD. An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome. J Gastroenterol Hepatol 2009;24: 243-24.
18. Targher G, Solagna E, Tosi F, Castello R, Spiazzi G, Zoppini G, et al. Abnormal serum alanine aminotransferase levels are associated with impaired insulin sensitivity in young women with polycystic ovary syndrome. J Endocrinol Invest 2009;32: 695-700.
19. Schwimmer JB, Khorram O, Chiu V, Schwimmer WB. Abnormal aminotransferase activity in women with polycystic ovary syndrome. Fertil Steril 2005;83: 494-7.
20. Markou A, Androulakis II, Mourmouris C, Tsikkini A, Samara C, Sougioultzis S, et al. Hepatic steatosis in young lean insulin resistant women with polycystic ovary syndrome. Fertil Steril 2010;93: 1220-6.
21. Rodin DA, Bano G, Bland JM, Taylor K, Nussey SS. Polycystic ovaries and associated metabolic abnormalities in Indian subcontinent Asian women. Clin Endocrinol (Oxf) 1998;49: 91-9.
22. Norman RJ, Mahabeer S, Master S. Ethnic differences in insulin and glucose response to glucose between white and Indian women with polycystic syndrome. Fertil Steril 1995;63: 58-62.
23. Wijeyaratne CN, Balen AH, Barth JH, Belchetz PE. Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: Is there a difference? Clin Endocrinol (Oxf) 2002;57: 343-50.
24. Kulshreshtha B, Ganie MA, Praveen EP, Gupta N, Lal Khurana M, Seith A, et al. Insulin response to oral glucose in healthy, lean young women and patients with polycystic ovary syndrome. Gynecol Endocrinol 2008;24: 637-43.
25. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, authors. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81: 19-25.
26. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001;285: 2486-97.
27. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in non alcoholic hepatic disease. Gasteroenterology 2002;123: 745-50.
28. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: A systematic review and meta-analysis. Hum Reprod Update 2010;16: 347-63.
29. Cussons AJ, Stuckey BG, Watts GF. Cardiovascular disease in the polycystic ovary syndrome: New insights and perspectives. Atherosclerosis 2006;185: 227-39.
30. Soares EM, Azevedo GD, Gadelha RG, Lemos TM, Maranhão TM. Prevalence of the metabolic syndrome and its components in Brazilian women with polycystic ovary syndrome. Fertil Steril 2008;89: 649-55.
31. Cheung LP, Ma RC, Lam PM, Lok IH, Haines CJ, So WY, et al. Cardiovascular risks and metabolic syndrome in Hong Kong Chinese women with polycystic ovary syndrome. Hum Reprod 2008;23: 1431-8.
32. Park HR, Choi Y, Lee HJ, Oh JY, Hong YS, Sung YA. The metabolic syndrome in young Korean women with polycystic ovary syndrome. Diabetes Res Clin Pract 2007;77: S243-6.
33. Bhattacharya SM. Prevalence of metabolic syndrome in women with polycystic ovary syndrome, using two proposed definitions. Gynaecol Endocrinol 2010;26: 516-20.
34. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 2003;52: 908-15.
35. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al. NASH and insulin resistance: Insulin hyper secretion and specific association with the insulin resistance syndrome. Hepatology 2002;35: 373-9.
36. Zheng RH, Ding CF. Prevalence of nonalcoholic fatty liver disease in patients with polycystic ovary syndrome: A case-control study. Zhonghua Fu Chan Ke Za Zhi 2008;43: 98-101.
37. Economou F, Xyrafis X, Livadas S, Androulakis II, Argyrakopoulou G, Christakou CD, et al. In overweight/obese but not in normal-weight women, polycystic ovary syndrome is associated with elevated liver enzymes compared to controls. Hormones (Athens) 2009;8: 199-206.
38. Kauffman RP, Baker TE, Baker V, Kauffman MM, Castracane VD. Endocrine factors associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome: Do androgens play a role? Gynecol Endocrinol 2010;26: 39-46.
39. Vassilatou E, Lafoyianni S, Vryonidou A, Ioannidis D, Kosma L, Katsoulis K, et al. Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Hum Reprod 2010;25: 212-20.
40. Gutierrez-Grobe Y, Ponciano-Rodríguez G, Ramos MH, Uribe M, Méndez-Sánchez N. Prevalence of non alcoholic fatty liver disease in premenopausal, postmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol 2010;9: 402-9.
41. Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: Causal effect or epiphenomenon? Diabetologia 2008;51: 1947-53.
42. Baranova A, Tran TP, Birerdinc A, Younossi ZM. Systematic review: Association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2011;33: 801-14.
43. Palmentieri B, de Sio I, La Mura V, Masarone M, Vecchione R, Bruno S, et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis 2006;38: 485-9.
44. Wieckowska A, Feldstein AE. Diagnosis of nonalcoholic fatty liver disease: Invasive versus noninvasive. Semin Liver Dis 2008;28: 386-95.